Log in

NYSEAMERICAN:DXRDaxor Stock Price, Forecast & News

$14.46
+0.52 (+3.73 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$13.01
Now: $14.46
$14.46
50-Day Range N/A
52-Week Range
$7.13
Now: $14.46
$17.90
Volume1,198 shs
Average Volume18,556 shs
Market Capitalization$54.18 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.17 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:DXR
CUSIPN/A
Phone+1-212-3308500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$54.18 million
Next Earnings DateN/A
OptionableNot Optionable

Receive DXR News and Ratings via Email

Sign-up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.

Daxor (NYSEAMERICAN:DXR) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Daxor?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daxor in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Daxor.

What price target have analysts set for DXR?

2 brokerages have issued 1 year price objectives for Daxor's stock. Their forecasts range from $18.00 to $22.00. On average, they expect Daxor's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 38.3% from the stock's current price. View analysts' price targets for Daxor.

Has Daxor been receiving favorable news coverage?

News headlines about DXR stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Daxor earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutDaxor.

Are investors shorting Daxor?

Daxor saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 29,200 shares, a decrease of 20.4% from the April 15th total of 36,700 shares. Based on an average daily volume of 28,100 shares, the short-interest ratio is presently 1.0 days. Approximately 3.6% of the shares of the stock are sold short. View Daxor's Current Options Chain.

Who are some of Daxor's key competitors?

What other stocks do shareholders of Daxor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daxor investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Pfizer (PFE), ContraFect (CFRX), Dynavax Technologies (DVAX), Micron Technology (MU), Sanofi (SNY), Verastem (VSTM) and Cidara Therapeutics (CDTX).

Who are Daxor's key executives?

Daxor's management team includes the following people:
  • Mr. Michael Richard Feldschuh, Chairman, Pres & CEO (Age 50)
  • Mr. Jonathan Adam Feldschuh, Chief Scientific Officer & Director (Age 54)
  • Mr. Robert J. Michel CPA, Chief Financial Officer (Age 62)
  • Ms. Kathryn A. Kornafel, VP of Marketing & Commercial Devel.
  • Mr. Guido Manzo, VP of Sales

What is Daxor's stock symbol?

Daxor trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "DXR."

Who are Daxor's major shareholders?

Daxor's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FNY Investment Advisers LLC (0.27%). Company insiders that own Daxor stock include Edward Feuer, Michael Richard Feldschuh and Robert J Michel. View institutional ownership trends for Daxor.

Which major investors are buying Daxor stock?

DXR stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Daxor stock in the last two years include Edward Feuer, Michael Richard Feldschuh, and Robert J Michel. View insider buying and selling activity for Daxor.

How do I buy shares of Daxor?

Shares of DXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Daxor's stock price today?

One share of DXR stock can currently be purchased for approximately $14.46.

How big of a company is Daxor?

Daxor has a market capitalization of $54.18 million.

What is Daxor's official website?

The official website for Daxor is www.daxor.com.

How can I contact Daxor?

Daxor's mailing address is 350 5th Ave Ste 4740, NEW YORK, NY 10118-0002, United States. The company can be reached via phone at +1-212-3308500.

This page was last updated on 6/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.